Genmab A/S (GMAB) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Genmab A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.420 Hello and welcome to the GENMAB first half 2025 financial results conference 00:00:05.420 -- 00:00:09.046 call. As a reminder, this conference call is being recorded. 00:00:09.046 -- 00:00:14.575 During this telephone conference, you may be presented with forward-looking statements 00:00:14.575 -- 00:00:20.605 that include words such as believes, anticipates, plans or expects. 00:00:20.605 -- 00:00:25.513 Actual results may differ materially, for example, as a result of delayed or unsuccessful 00:00:25.513 -- 00:00:30.536 development projects. GENMAB is not under any obligation to update 00:00:30.536 -- 00:00:35.782 statements regarding the future nor to confirm such statements in relation 00:00:35.782 -- 00:00:40.088 to the actual results unless this is required by law. 00:00:40.088 -- 00:00:45.574 Please note that GENNAB may hold your personal data as indicated by you as 00:00:45.574 -- 00:00:50.801 part of our investor relations outreach activities in order to update you on GENNAB 00:00:50.801 -- 00:00:56.140 going forward. Please refer to our website for more information on GenMap 00:00:56.140 -- 00:00:58.463 and our privacy policy. 00:00:58.463 -- 00:01:02.529 I would now like to turn the conference over to your first speaker today, Jan van de 00:01:02.529 -- 00:01:05.614 Winkel. Please go ahead. 00:01:05.614 -- 00:01:09.059 Hello, and welcome to our financial results for the first half of 2025. 00:01:09.059 -- 00:01:11.640 With me today 00:01:12.144 -- 00:01:15.609 is our Chief Financial Officer, Anthony Pagano, 00:01:15.609 -- 00:01:19.075 our Chief Commercial Officer, Brad Bailey, 00:01:19.075 -- 00:01:22.415 and our Chief Medical Officer, Tai Yamadi. 00:01:22.415 -- 00:01:28.380 And for the Q&A, we will be joined by our Ch...